Physician profile
Kent C Shih
NPI 1619075207
$899,698.43
in general payments reported to CMS, 2019-2025
82 companies · $135K in 2025
The $135K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $51K · 2021: $142K · 2022: $202K · 2023: $150K · 2024: $124K · 2025: $135K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $312K · Consulting Fee: $53K · Travel and Lodging: $32K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $311,800.70 |
| Consulting Fee | $53,254.75 |
| Travel and Lodging | $31,852.69 |
| Food and Beverage | $11,615.48 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $473,055.66 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Regeneron Healthcare Solutions, INC. | $297,293.72 | 2019-2025 | Libtayo |
| Genzyme Corporation | $40,628.62 | 2019-2025 | |
| Janssen Biotech, INC. | $33,524.85 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Emd Serono, INC. | $30,973.27 | 2019-2025 | Bavencio |
| Novartis Pharmaceuticals Corporation | $3,552.73 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $2,666.31 | 2021-2025 | Fotivda |
| Astrazeneca Pharmaceuticals Lp | $2,623.26 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Novocure INC. | $2,553.15 | 2020-2025 | Optune Gio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,362.63 | 2024-2025 | Gilotrif |
| Bristol Myers Squibb Company | $1,785.00 | 2023 | |
| Celgene Corporation | $1,647.68 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $961.93 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $384.03 | 2019-2025 | Polivy, Tecentriq Hybreza, Venclexta |
| Monteris Medical Corporation | $357.59 | 2019-2024 | Neuroblate |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $293.96 | 2019-2025 | |
| Pfizer INC. | $270.59 | 2019-2025 | |
| Eisai INC. | $258.64 | 2019-2025 | |
| Amgen INC. | $256.54 | 2019-2024 | Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $255.21 | 2019-2025 | Alunbrig, Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $235.83 | 2022-2025 | Enhertu |
| Abbvie INC. | $229.55 | 2019-2025 | Venclexta |
| Gilead Sciences, INC. | $193.03 | 2019-2025 | Trodelvy |
| Incyte Corporation | $191.89 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Astellas Pharma US INC | $183.46 | 2019-2025 | Padcev, Vyloy, Xospata |
| Alexion Pharmaceuticals, INC. | $151.91 | 2019-2024 | Ultomiris |
| Janssen Scientific Affairs, LLC | $150.00 | 2023 | Erleada, Pipeline |
| Array Biopharma INC | $126.45 | 2019-2024 | Mektovi, Xalkori, Lorbrena |
| Jazz Pharmaceuticals INC. | $122.32 | 2019-2025 | |
| Exelixis INC. | $118.52 | 2019-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $114.63 | 2023-2025 | |
| Lilly USA, LLC | $113.67 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $113.19 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Rigel Pharmaceuticals, INC. | $108.97 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genmab U.S., INC. | $102.96 | 2024-2025 | Epkinly |
| Tersera Therapeutics LLC | $101.78 | 2023-2025 | Zoladex, Xermelo |
| Puma Biotechnology, INC. | $99.26 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $92.47 | 2023-2025 | |
| Stemline Therapeutics INC. | $76.54 | 2023-2025 | Orserdu |
| Teva Pharmaceuticals USA, INC. | $72.91 | 2019-2020 | |
| Taiho Oncology, INC. | $72.07 | 2019-2024 | |
| Seagen INC. | $66.44 | 2020-2023 | Tukysa |
| Sobi, INC | $64.86 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $64.47 | 2019-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $61.96 | 2019-2024 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $59.58 | 2024 | Cosela, Monoferric |
| Tesaro, INC. | $53.77 | 2019 | |
| Iovance Biotherapeutics, INC. | $50.89 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $50.00 | 2024-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $46.27 | 2024-2025 | Besremi |
| Blueprint Medicines Corporation | $45.08 | 2025 | Ayvakit |
| Heron Therapeutics, INC. | $43.69 | 2019 | |
| Clovis Oncology, INC. | $42.21 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $41.40 | 2024-2025 | Qinlock, Romvimza |
| G1 Therapeutics, INC. | $40.48 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $38.69 | 2023-2024 | Krazati |
| Cti Biopharma Corp. | $35.60 | 2023 | Vonjo |
| Beone Medicines USA, INC. | $29.82 | 2025 | Tevimbra |
| Tempus Ai, INC | $27.34 | 2025 | Xt Cdx |
| Spectrum Pharmaceuticals INC. | $26.76 | 2019 | |
| Aurobindo Pharma USA, INC. | $25.92 | 2019 | |
| Geron Corporation | $24.11 | 2025 | Rytelo |
| Verastem, INC. | $23.05 | 2019 | |
| Shield Therapeutics INC | $22.28 | 2025 | |
| Cycle Pharmaceuticals INC | $21.67 | 2025 | Phyrago |
| Coherus Oncology, INC. | $21.52 | 2024 | |
| Sun Pharmaceutical Industries INC. | $20.60 | 2024 | |
| Macrogenics, INC. | $20.54 | 2023 | |
| Morphosys, US INC. | $20.21 | 2023 | Monjuvi |
| Beigene USA, INC. | $19.15 | 2025 | Tevimbra |
| Karyopharm Therapeutics INC. | $18.67 | 2020 | |
| Capsovision, INC. | $15.22 | 2025 | Capsocam Plus |
| Eusa Pharma (US) LLC | $14.59 | 2019 | |
| Secura Bio, INC. | $13.67 | 2019 | |
| Foundation Medicine, INC. | $13.39 | 2020 | |
| Kite Pharma, INC. | $13.34 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.59 | 2019 | |
| Dova Pharmaceuticals | $11.82 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$261.01 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.